{"doi":"10.1002/art.43383","title":"Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease","abstract":"OBJECTIVE: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. METHODS: We first assessed the association of a panel of IPF-associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF-related biomarkers (eotaxin, Flt-3L, interleukin-8, macrophage-derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP-2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP-2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. RESULTS: In both development cohorts, participants with RA-ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18-3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55-3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. CONCLUSION: A multibiomarker panel derived from IPF-associated biomarkers was associated with RA-ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA-ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.","journal":"Arthritis & Rheumatology","year":2025,"id":534721,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9541,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":352759,"name":"Daniel J. Kass","orcid":"0000-0001-6597-7830","position":1,"is_corresponding":false},{"id":1364965,"name":"Joshua F. Baker","orcid":"0000-0003-0170-028X","position":2,"is_corresponding":false},{"id":366000,"name":"Michael J. Duryee","orcid":"0000-0001-9104-2238","position":3,"is_corresponding":false},{"id":315984,"name":"Yangyuna Yang","orcid":null,"position":4,"is_corresponding":false},{"id":315983,"name":"Punyasha Roul","orcid":null,"position":5,"is_corresponding":false},{"id":1368082,"name":"Halie Frideres","orcid":"0009-0008-1752-0949","position":6,"is_corresponding":false},{"id":497055,"name":"Katherine D. Wysham","orcid":"0000-0001-8707-7649","position":7,"is_corresponding":false},{"id":61593,"name":"Paul A. Monach","orcid":"0000-0003-4937-0515","position":8,"is_corresponding":false},{"id":372692,"name":"Andreas Reimold","orcid":null,"position":9,"is_corresponding":false},{"id":755681,"name":"Gail S. Kerr","orcid":"0000-0002-4930-3235","position":10,"is_corresponding":false},{"id":862588,"name":"Gary Kunkel","orcid":null,"position":11,"is_corresponding":false},{"id":755682,"name":"Grant W. Cannon","orcid":"0000-0001-6640-9173","position":12,"is_corresponding":false},{"id":476885,"name":"Scott M. Matson","orcid":"0000-0002-3748-9597","position":13,"is_corresponding":false},{"id":457086,"name":"Jill A. Poole","orcid":"0000-0002-6236-2563","position":14,"is_corresponding":false},{"id":342502,"name":"Geoffrey M. Thiele","orcid":"0000-0001-5688-8596","position":15,"is_corresponding":false},{"id":314417,"name":"Ted R. Mikuls","orcid":"0000-0002-0897-2272","position":16,"is_corresponding":false},{"id":314415,"name":"Bryant R. England","orcid":"0000-0002-9649-3588","position":17,"is_corresponding":false},{"id":685291,"name":"Dana P. Ascherman","orcid":"0000-0002-1387-0860","position":18,"is_corresponding":false},{"id":443092,"name":"Brent A. Luedders","orcid":"0000-0001-6717-9680","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-19T02:51:52.019261Z","pmid":"40955640","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}